Write in a clean editor, then format for Crohn s & Colitis 360 in one click — DocuGuru applies the official Oxford University Press template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Crohn s & Colitis 360 is a peer-reviewed journal published by Oxford University Press, covering Inflammatory Bowel Disease, Microscopic Colitis, Rheumatoid Arthritis Research and Therapies.
| Publisher | Oxford University Press |
|---|---|
| Reference style | Author–year (OUP) Author–year — (Smith, 2023) in the text Smith, A., Jones, B. and Lee, C. (2023) 'A representative article title', Crohn s & Colitis 360, 12(3), pp. 45–58.
Formats any DOI in the closest standard style — Crohn s & Colitis 360 has no published style definition, so this is an approximation. No sign-up. |
| Publishes research in | Inflammatory Bowel Disease Microscopic Colitis Rheumatoid Arthritis Research and Therapies Biosimilars and Bioanalytical Methods Autoimmune and Inflammatory Disorders |
| ISSN | 2631-827X |
| Citation impact (2-yr) | 2.07 |
| h-index | 25 |
| i10-index | 116 |
| Total citations | 3,508 |
| Article processing charge | $2,975 |
| Open access | Yes |
| Top institutions publishing here | University of North Carolina at Chapel Hill |
| Journal website | academic.oup.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Background: Given rapid innovation in advanced therapies for moderately to severely active ulcerative colitis (UC), we investigated their comparative efficacy and safety during induction and maintenance through network meta-analysis. Methods: Using Bayesian methods, endpoints of clinical remission and clinical response per Full Mayo score, and endoscopic improvement were assessed in bio-naive and -exposed populations. Safety…
Background: Understanding ulcerative colitis disease activity assessed via the full, modified, or partial Mayo Score may help clinicians apply results from clinical trials to practice and facilitate interpretation of recent and older studies. Methods: Mayo Score variables were assessed in a cross-sectional study of 2608 ulcerative colitis patients. Results: Permutations of Mayo Scores were highly…
Abstract Background Short non-coding microRNAs (miRNAs) are involved in various cellular processes during disease progression of Crohn’s disease (CD) and remarkably stable in feces, which make them attractive biomarker candidates for reflecting intestinal inflammatory processes. Here we investigated the potential of fecal miRNAs as noninvasive and translational CD biomarkers. Methods MiRNAs were screened in feces…
Background: Bowel urgency reduces ulcerative colitis patients' quality of life. Mirikizumab, a p19-directed anti-IL-23 antibody, demonstrates ulcerative colitis efficacy. Mirikizumab efficacy to reduce bowel urgency and bowel urgency association with other endpoints were analyzed in 2 Phase 3 trials. Methods: LUCENT-1 (Induction): 1162 patients randomized 3:1 to intravenous 300 mg mirikizumab or placebo every 4…
Abstract Background Ustekinumab has been recently approved for the treatment of moderately to severely active ulcerative colitis (UC). The registry trials for ustekinumab in UC demonstrated efficacy and safety, but data on real-world outcomes are limited. We describe the effectiveness and safety of ustekinumab in patients with UC from 2 US tertiary inflammatory bowel disease…
